Article
PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations.
International journal of molecular sciences - 19 Apr 2022
Mansour Mohammed S I, Malmros Karina, Mager Ulrich, Ericson Lindquist Kajsa, Hejny Kim, Holmgren Benjamin, Seidal Tomas, Dejmek Annika, Dobra Katalin, Planck Maria, Brunnström Hans
Abstract excerpt
Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1) have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 expression, detected by immunohistochemistry (IHC) typically on formalin-fixed paraffin-embedded (FFPE) histological specimens, is linked to better response. Following our previous investigation on PD-L1 in cytological samples, the aim of this...
Topics
- Adenocarcinoma
- B7-H1 Antigen
- Carcinoma, Non-Small-Cell Lung
- ErbB Receptors
- Humans
- Ligands
- Lung Neoplasms
- Mutation
- Proto-Oncogene Proteins p21(ras)
- Retrospective Studies
